### ARTICLE

### Open Access

# ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation

Eunhee Park<sup>1</sup> and Su Wol Chung<sup>1</sup>

#### Abstract

Ferroptosis is a novel form of programmed cell death in which the accumulation of intracellular iron promotes lipid peroxidation, leading to cell death. Recently, the induction of autophagy has been suggested during ferroptosis. However, this relationship between autophagy and ferroptosis is still controversial and the autophagy-inducing mediator remains unknown. In this study, we confirmed that autophagy is indeed induced by the ferroptosis inducer erastin. Furthermore, we show that autophagy leads to iron-dependent ferroptosis by degradation of ferritin and induction of transferrin receptor 1 (TfR1) expression, using wild-type and autophagy-deficient cells, BECN1<sup>+/-</sup> and LC3B<sup>-/-</sup>. Consistently, autophagy deficiency caused depletion of intracellular iron and reduced lipid peroxidation, resulting in cell survival during erastin-induced ferroptosis. These data provide evidence that ROS-induced autophagy is a key regulator of ferritin degradation and TfR1 expression during ferroptosis. Our study thus contributes toward our understanding of the ferroptotic processes and also helps resolve some of the controversies associated with this phenomenon.

#### Introduction

Iron is essential for the survival of nearly all organisms, as it serves as a cofactor for a host of biochemical processes, including oxygen storage, oxidative phosphorylation, and enzymatic reactions required for cellular proliferation<sup>1</sup>. However, the levels of free iron in a cell must be tightly regulated to avoid the generation of reactive oxygen species (ROS) via the Fenton reaction<sup>2</sup>. Transferrin receptor 1 (TfR1) and ferritins are well-known regulators of cellular iron. TfR1 is a transmembrane glycoprotein responsible for internalizing the transferrin-bound iron, which is then released into the cytoplasm and stored in a non-toxic form inside metal-loprotein complexes called ferritins<sup>3</sup>. Ferritin is a complex

Correspondence: Su Wol Chung (swchung@ulsan.ac.kr)

of 24 subunits, consisting of two basic subunits: a heavy subunit (FTH1) and a light subunit (FTL).

Autophagy is the natural, regulated, destructive biological process that disassembles unnecessary or dysfunctional components of a cell<sup>4</sup>. The core machinery of autophagy consists of over 30 autophagy-related proteins, including BECN1 and LC3B. During autophagy, doublemembrane vesicles are formed that engulf the damaged proteins and organelles and fuse with lysosomal vesicles<sup>5</sup>. BECN1 is an autophagosome initiation protein and LC3B is a structural component of the autophagosomes<sup>6</sup>. Autophagy is generally a stress-responsive survival mechanism. However, a controversial theory is that autophagy may also be a cell death mechanism i.e., autophagic cell death<sup>7,8</sup>. Recent studies have shown that autophagy degrades the iron-storage macromolecule ferritin, termed as ferritinophagy<sup>9</sup>. Degradation of ferritin increases the cellular iron levels, leading to accumulation of ROS and ultimately cell death.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, and indicate if material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

 <sup>&</sup>lt;sup>1</sup>School of Biological Sciences, College of Natural Sciences, University of Ulsan,
93 Daehak-ro, Nam-gu, Ulsan 44610, South Korea
Edited by A. Stephanou

<sup>©</sup> The Author(s) 2019



Ferroptosis is a novel form of regulated cell death, characterized by an iron-dependent increase in lipid peroxidation. However, this process has not yet been welldefined in a chronological manner<sup>10,11</sup>. Erastin is a small molecule that is capable of triggering ferroptosis<sup>11</sup>. The ferroptotic cell death triggered by erastin is significantly inhibited by antioxidants (e.g.,  $\alpha$ -tocopherol, butylated hydroxytoluene, and  $\beta$ -carotene) and iron chelators (e.g., deferoxamine), suggesting that ROS- and iron-dependent signaling is required for erastin-induced ferroptosis<sup>11</sup>. According to the original study by the Stockwell group in 2012, erastin-induced ferroptosis in fibrosarcoma cells lacks the morphological and biochemical characteristics of apoptosis, necrosis, and autophagy<sup>11</sup>. However, recent studies have suggested that genetic inhibition of the autophagy pathway regulates the process and function of ferroptosis<sup>12-14</sup>. Whether ferroptosis and autophagyinduced cell death are dependent upon each other is currently controversial and not well understood. In this study, we have investigated a direct correlation between ferroptosis and autophagy using wild-type and autophagydeficient fibroblastic cells. We found that erastin-induced ferroptotic cell death and intracellular iron levels are depleted in autophagy-deficient cells. Interestingly, erastin-enhanced early ROS seems to induce the autophagy process in fibroblastic cells.

#### Results

#### Erastin induces autophagy-dependent cell death

Ferroptosis is a newly discovered iron-dependent process of cell death<sup>11</sup>. To investigate the role of autophagy in erastin-induced ferroptotic cell death, we harvested lung fibroblastic cells from  $BECN1^{+/-}$ ,  $LC3B^{-/-}$ , and wild-type mice and characterized the primary lung fibroblast cell using rapamycin treatment (Supplementary Fig. 1). The BECN1<sup>+/-</sup>, LC3B<sup>-/-</sup>, and wild-type fibroblasts were treated with different concentrations of vehicle (control) or erastin for different time durations, and the cell viability was measured. The viability of BECN1<sup>+/-</sup> and LC3B<sup>-/-</sup> fibroblastic cells was enhanced in presence of 2 µM erastin (93.14% and 94.86%, respectively) and  $10\,\mu M$  erastin (72.01% and 81.14%, respectively), compared with that of wild-type cells treated with  $2 \mu M$  (72.29%) or  $10 \mu M$ (30.86%) erastin (Fig. 1a) and were similar results using propidium iodide (PI) staining (Supplementary Fig. 2). Further, the cell viability decreased after  $5\,\mu M$  erastin treatment for 8 h (71.42%) and 24 h (30.57%) in wild-type cells, but not in BECN1<sup>+/-</sup> and LC3B<sup>-/-</sup> fibroblastic cells (Fig. 1b). To examine whether erastin could induce the cell death in other primary human dermal neonatal fibroblastic cells (HDFn) or foreskin adult fibroblastic cells (NuFF), we treated these cells with erastin and then performed a cell viability assay. Significant increases in

cell death were observed in both human primary fibroblastic cells by WST-1 assay (Fig. 1c). No significant differences in cell death were observed between human and mouse cells. In addition, to ascertain whether the enhanced cell viability in BECN1<sup>+/-</sup> and LC3B<sup>-/-</sup> cells is specific to erastin treatment, we treated these and wildtype cells with the cell death inducer, auranofin. A similar level of cell death was observed in BECN1<sup>+/-</sup>, LC3B<sup>-/-</sup>, and wild-type fibroblastic cells 24 h after auranofin administration (Fig. 1d), suggesting that the effects were erastin-specific. Moreover, knockdown of BECN1 or LC3B by siRNA prevented erastin-induced cell death in wild-type fibroblastic cells (Fig. 2). These data together suggest that the erastin-induced cell death in primary fibroblastic cells is associated with the autophagy process.

### Inhibition of autophagy disrupts erastin-triggered cell death

To verify whether erastin induces autophagy, we examined whether autophagy levels change in the presence of erastin in wild type, BECN1<sup>+/-</sup>, or LC3B<sup>-/-</sup> fibroblastic cells. We treated these fibroblastic cells with vehicle or various doses of erastin (2, 5, or 10 µM) and harvested total protein 24 h after cell treatment. LC3B is a central protein in the autophagy pathway and is widely used as a biomarker of autophagosome<sup>15</sup>. In wild-type fibroblastic cells, the levels of LC3B-II (lower band of LC3B) protein was found to increase upon treatment with low dose of erastin  $(2 \mu M)$ , and a more striking increase was evident at higher doses of erastin (5 and  $10 \,\mu$ M), compared with treatment with vehicle (Fig. 3a, b). However, enhanced levels of LC3B-II were not observed in BECN1<sup>+/-</sup> and LC3B<sup>-/-</sup> fibroblastic cells after erastin treatment (Fig. 3a, b), suggesting that the erastin-induced LC3B-II expression is dependent on the autophagy process. To confirm whether increases in LC3B activation correlated with increased autophagic flux during the erastin treatment, we repeated these experiments by treating cells with erastin in the presence or absence of 3methylaldehyde (3-MA), an inhibitor of phosphatidylinositol 3-kinase (PI3K) that blocks autophagosome formation, or chloroquine (CQ), an inhibitor of autophagosome-lysosome fusion. Treatment with 3-MA further decreased the activation of LC3B-II in vehicle or erastin-treated wild-type fibroblasts, indicative of autophagic activity (Fig. 3c). Consistently, CQ treatment further elevated the activation of LC3B-II in wild-type fibroblasts (Fig. 3c). In contrast, the erastin-treated  $BECN1^{+/-}$  and  $LC3B^{-/-}$  fibroblastic cells did not show decreased or elevated activation of LC3B-II upon 3-MA or CQ treatments, respectively (Fig. 3c, d). Next, to determine the role of autophagy in erastin-triggered cell death, we used a WST-1 assay to determine whether the autophagy inhibitors affected erastin-induced cell viability in wild type, BECN1<sup>+/-</sup>, and LC3B<sup>-/-</sup> fibroblasts. As shown in Fig. 3e, in wild-type fibroblasts, the erastin-induced cell death recovered in the presence of autophagy inhibitors, 3-MA or CQ, compared with erastin treatment alone. However, similar treatment had no effect on BECN1<sup>+/-</sup>, and LC3B<sup>-/-</sup> fibroblast cells (Fig. 3e). These data indicate that erastin-induced ferroptosis is an autophagy-dependent process and autophagy is a key activator of erastin-induced cell death.

## Depletion of autophagy attenuates lipid peroxidation in erastin-induced ferroptosis

ROS accumulation is one of the hallmarks of ferroptosis. Consistently, ferroptosis inhibitors (such as ferrostatin) and various antioxidants or ROS scavengers can all completely inhibit cellular ROS accumulation and ferroptotic cell death<sup>16</sup>. We, thus, hypothesized that depletion of autophagy protein levels such as BECN1 or LC3B may contribute to the regulation of erastin-induced ROS production and cell death in fibroblastic cells. To investigate the role of autophagy in lipid peroxidation, wild type, BECN1<sup>+/-</sup>, and LC3B<sup>-/-</sup> fibroblastic cells were treated with vehicle or erastin and the cytosolic reactive oxygen species (ROS) (Fig. 4a) and lipid peroxidation (Fig. 4b) were assayed by flow cytometry using the fluorescent probes CellROX and C11-BODIPY, respectively. As shown in Fig. 4a, b, erastin treatment increased cytosolic ROS and lipid peroxidation (38.81% and 47.76%, respectively) compared with vehicle (6.97% and 4.72%, respectively) in wild-type fibroblastic cells, but not in BECN1<sup>+/-</sup> and  $LC3B^{-/-}$  fibroblastic cells. To verify whether the erastin-induced lipid peroxidation is dependent on the autophagy pathway, wild-type fibroblastic cells were treated with autophagy inhibitors, CO, or bafilomycin A1 (Baf A1), blocker of the fusion between autophagosomes and lysosomes, in the absence or presence of erastin. The erastin-induced cytosolic ROS and lipid peroxidation were disrupted upon inhibition of the autophagy process by the administration of CQ (3.51% and 13.25%, respectively) and Baf A1 (5.02% and 10.25%, respectively), compare with erastin treatment alone (36.75% and 61.25%, respectively) (Fig. 4c, d). These data suggest that autophagy might positively regulate erastin-triggered cell death by increasing lipid peroxidation.

## Autophagy deficiency inhibits erastin-induced intracellular levels of iron

Erastin-induced ferroptotic cell death involves the accumulation of intracellular iron, resulting in the production of cytosolic and lipid  $\mathrm{ROS}^{11}$ . We, therefore, examined the intracellular iron content in wild-type and autophagy-deficient cells upon various treatments. Intracellular levels of total iron were increased 24 h after erastin (5  $\mu$ M) administration in wild-type fibroblastic cells,



siRNA and western blot was performed to verify the downregulation of BECN1 or LC3B expression (**a**, **b**, respectively).  $\beta$ -actin was used as loading control. Cell viability was measured in control (n = 3), BECN1 (n = 3), or LC3B (n = 3) siRNA transfected cells 24 h after vehicle or different doses of erastin treatment (**c**, **d**). All data shown are the mean  $\pm$  SD from three independent experiments. \*P < 0.05 indicates significant increase compared with control siRNA







but not in  $BECN1^{+/-}$  and  $LC3B^{-/-}$  fibroblastic cells. Furthermore, erastin-induced intracellular iron in wildtype fibroblastic cells was found to decrease in the presence of the antioxidant, NAC (Fig. 5a). However, NAC treatment of BECN1<sup>+/-</sup> and LC3B<sup>-/-</sup> fibroblastic cells had no effect on the intracellular iron content (Fig. 5a). The intracellular levels of iron can increase upon degradation of iron protein complexes, such as ferritin, which forms a complex of 24 subunits consisting of a mixture of ferritin heavy (FTH) and light chains (FTL)<sup>17</sup>. Especially, ferritin is degraded via a recently identified autophagic process, ferritinophagy, and FTH1 is a substrate of ferritinophagy leading to lysosomal degradation<sup>18,19</sup>. Therefore, we determined whether low levels of intracellular iron in autophagy-deficient cells were related to autophagy-mediated degradation of FTH1 in the presence of erastin. We treated wild-type or autophagy-deficient LC3B<sup>-/-</sup> fibroblastic cells with vehicle or erastin and harvested total protein 2, 4, 6, 8, or 10 h after treatment. The protein levels of FTH1 were found to decrease over time in wild-type fibroblastic cells in the presence of erastin (Fig. 5b). However, protein levels of FTH1 were enhanced in autophagy deficient, LC3B<sup>-/-</sup>, fibroblastic

erastin treatment, and then the protein levels of FTH1 were determined. After erastin administration, protein levels of FTH1 decreased in wild-type fibroblastic cells, but increased in 3-MA-pretreated wild-type fibroblastic cells (Fig. 5c). The transferrin receptor (TfR1) is needed for the import of iron into the cell and is regulated in response to intracellular iron concentration<sup>20</sup>. Therefore, we analyzed the protein levels of TfR1 in autophagydeficient cells (LC3B<sup>-/-</sup>) and autophagy inhibited cells (by inhibitor 3-MA), after erastin administration (Fig. 5b, c). The protein levels of TfR1 were increased after 6 h of erastin administration in wild-type fibroblastic cells (Fig. 5b, c). However, decreased levels of TfR1 were found 2 h after erastin administration in autophagy inhibitor (3MA)-treated wild-type fibroblastic cells (Fig. 5c). Interestingly, the protein levels of TfR1 were not increased in autophagy-deficient cells (LC3B<sup>-/-</sup>) after erastin administration (Fig. 5c). To verify whether autophagy is involved in iron-dependent cell death by erastin, we next observed the cell viability 24 h after

cells (Fig. 5b). To confirm that the degradation of ferritin

occurred via the autophagy pathway, the cells were pre-

treated with the autophagy inhibitor 3-MA for 1 h before



erastin treatment in the absence or presence of iron chelator, deferiprone (DFP). Erastin-induced cell death recovered in the presence of iron chelator, DFP, in wildtype fibroblastic cells, but not in autophagy-deficient fibroblastic cells and DFP recovery was more partial than ROS inhibition and other previous treatments (Fig. 5d). These data suggest that autophagy is a key regulator for controlling the intracellular iron levels through ferritin degradation and the expression of TfR1 in response to erastin.

#### Erastin-enhanced ROS leads to autophagy

To confirm whether autophagy-induced ROS production is involved in erastin-induced cell death, we examined the impact of the antioxidant N-acetylcysteine (NAC) or the mitochondria-specific antioxidant mito-TEMPO on erastin-induced cell death in wild type,  $BECN1^{+/-}$ , and  $LC3B^{-/-}$  fibroblastic cells. Pre-treatment with NAC or mito-TEMPO significantly recovered cell

Official journal of the Cell Death Differentiation Association

viability in wild-type fibroblastic cells (Fig. 6a, b). However, pre-treatment with NAC or mito-TEMPO had no significant effects on erastin-induced cell death in  $BECN1^{+/-}$  and  $LC3B^{-/-}$  fibroblastic cells (Fig. 6a, b). To further investigate whether erastin-induced ROS triggered autophagy, we treated wild-type fibroblastic cells with vehicle, erastin (5 µM) or erastin plus ROS inhibitors (NAC and mito-TEMPO), iron chelator (deforoxamine, DFO), or inhibitor for lipid peroxidation (ferrostatin-1) and harvested total protein 2, 4, 6, 8, or 10 h after cell treatment. Erastin treatment increased the levels of LC3B-II (lower band of LC3B) protein, while treatment with ROS inhibitors (NAC and mito-TEMPO) blocked autophagy in wild-type fibroblastic cells (Fig. 6c, d). However, erastin-induced autophagy was not blocked in the presence of iron chelator (deferoxamine, DFO) or inhibitor for lipid peroxidation (ferrostatin-1) (Fig. 6e, f). These data suggest that erastin-induced ROS triggers autophagy and results in increasing intracellular iron.



#### Discussion

Ferroptosis is characterized as a type of programmed cell death that results from iron-dependent lipid peroxidation and is different from other types of cell death, especially autophagy<sup>21</sup>. In this study, we found that a ferroptotic inducer, erastin, enhanced the amount of LC3B-II in wild-type fibroblastic cells. Furthermore, viability of autophagy-deficient LC3B<sup>-/-</sup> fibroblastic cells increased in the presence of erastin, compared with that of wild-type cells. Autophagy is a cellular catabolic degradation response to starvation or stress whereby cellular proteins, organelles and cytoplasm are engulfed, digested and recycled to sustain cellular metabolism<sup>22</sup>. Autophagy pathway is also used for the elimination of pathogens and for the engulfment of apoptotic cells<sup>23,24</sup>. However, the effect of these events on ferroptosis is not well understood. Although recent publications report a role of autophagy in ferroptotic cell death in breast cancer cells and wild-type mouse embryonic fibroblasts, their observations were contradictory<sup>12–14,25</sup>. Among the initial publications, Jiang's group demonstrated that erastinenhanced LC3 conversion in mouse embryonic fibroblasts (MEFs) and HT1080 cells and erastin-induced cell death were inhibited in the presence of autophagy inhibitors, suggesting that ferroptosis is an autophagic cell death process<sup>13</sup>. On the other hand, Gibson's group insisted that

by degradation of ferritin<sup>14</sup>. In their study, siramesine, a lysosome disruptor, and lapatinib, a dual tyrosine kinase inhibitor, initially induced ferroptotic cell death, but switched to autophagic cell death later on in breast cancer cells. Different inducers and cell types may induce different cellular mechanisms for ferroptotic cell death. However, in our study, erastin-induced ferroptotic cell death was clearly inhibited in autophagy-deficient  $BECN^{+/-}$  and  $LC3B^{-/-}$  fibroblastic cells (Fig. 1). This phenomena was confirmed by inhibition of erastininduced ferroptotic cell death in the presence of autophagy inhibitors in wild type, BECN<sup>+/-</sup>, or LC3B<sup>-</sup> fibroblastic cells (Fig. 3e). Our data strongly support the initial theory that ferroptosis is as an autophagic cell death process. Furthermore, we verified that erastin-increased reactive oxygen species (ROS) induced LC3B conversion and activated autophagy (Fig. 6). With respect to the role of autophagy in ferroptosis,

the autophagy-induced cell death during ferroptosis occurred independently in breast cancer  ${\rm cells}^{12}$  and Hou's

group also suggested that autophagy promotes ferroptosis

with respect to the role of autophagy in ferroptosis, they demonstrated that autophagy regulates ferroptosis by regulating cellular iron homeostasis and cellular ROS generation<sup>13</sup>. Iron is a requisite metal in almost all biological systems. However, the levels of iron in the cell need to be tightly regulated, as an excess of iron can have damaging effects due to the generation of ROS<sup>26</sup>. Especially, autophagy can lead to the degradation of cellular iron stock protein ferritin and thus cause an increase of cellular labile iron levels, via NCOA4-mediated autophagy pathway, termed as ferritinophagy. High levels of cellular labile iron ensure rapid accumulation of cellular ROS, which is essential for ferroptosis<sup>14</sup>. Our data showed that the levels of intracellular iron were less in the autophagydeficient cells compared with wild-type fibroblastic cells (Fig. 5). Consistently, the heavy subunit of ferritin, ferritin heavy chain 1 (FTH1), was degraded by erastin in wildtype cells, but not in autophagy-deficient cells, or in wildtype cells in presence of the autophagy inhibitor, 3MA (Fig. 5b, c), indicating that autophagy regulates the intracellular iron levels during erastin-induced ferroptotic process. Transferrin receptor is a carrier protein for transferrin, an iron-binding plasma protein, thus controlling the level of intracellular iron levels<sup>20</sup>. Interestingly, the protein levels of transferrin receptor (TfR1) were enhanced by erastin in wild-type cells, but not in autophagy-deficient cells and autophagy inhibitor-treated wild-type cells (Fig. 5b, c). Thus, our results demonstrate that autophagy regulates intracellular iron levels through ferritin degradation and transferrin receptor induction. Although autophagy has been reported during ferroptosis, the mediator of autophagy induction was not known. Gibson's group suggested that prolonged iron-mediated ROS generation can induce autophagy<sup>12</sup>. However, our data showed that ROS inhibitors, NAC and mito-TEMPO, decreased erastin-induced autophagy, although the iron chelator, DFO, or lipid peroxidation inhibitor, ferrostatin-1 could not (Fig. 6). This indicates that ironindependent ROS is involved in induction of erastinmediated autophagy.

#### Materials and methods Reagents

Primary human dermal neonatal fibroblast (HDFn) and foreskin adult fibroblast (NuFF) cells were purchased from ATCC (Manassas, VA, USA), and cultured in DMEM medium (Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco, Waltham, MA, USA) and 1X Antibiotic-Antimycotic (100 U/mL penicillin, 100 µg/ mL streptomycin, Fungizone<sup>®</sup> 0.25 µg/mL, Gibco, Waltham, MA, USA) at 37 °C in a humidified incubator with 5% CO<sub>2</sub>. Mito-TEMPO was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Erastin, 3-MA, chloroquine, deferipron, and NAC were from Sigma-aldrich (St. Louis, MO, USA). The following antibodies were purchased by Santa Cruz Biotechnology (Santa Cruz, CA, USA): anti-APG5 (sc-33210), anti-BECN1 (sc-11427), anti-LC3B (L7543), and anti-β-actin (sc-81178).

#### Preparation of primary fibroblast from mouse lung

Primary pulmonary fibroblasts were isolated from  $LC3B^{-/-}$ ,  $BECN1^{+/-}$  mice and wild-type littermates, as previously described<sup>24</sup>. The lung tissue was soaked in a 1% antibiotic-antimycotic PBS (Invitrogen, Carlsbad, CA) twice for 20 min. The tissue was minced into 1-mm pieces, which were plated onto 100 mm dishes (30–40 pieces per plate). Fetal bovine serum was added dropwise over each tissue piece, and then the plates were incubated for 4 h at 37 °C. Then 2 mL of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics was added to each plate. The plates were restored to the incubator and monitored every day until the fibroblasts reached confluence.

#### Cell viability assay and propidium iodide (PI) staining assay

WST-1 assay was performed according to the manufacturer's instructions (Roche, Indianapolis, IN, USA) with 10 µL of WST-1 reagent was added to each well of a 96-well plate  $(1 \times 10^3 \text{ cells/well})$ . After 1 h of incubation using CO<sub>2</sub> incubator, the conversion of WST-1 reagent into chromogenic formazan was monitored with a spectrophotometer. On day 1 after plating, cells were treated with various doses  $(2, 5, and 10 \,\mu\text{M})$  and times  $(8, 10 \,\mu\text{M})$ 16, and 24 h) of erastin (Sigma, St. Louis, MO), respectively. PI staining assay was analyzed using flow cytometry. Fibroblast cells were seeded in 6-well plates at a density of  $3 \times 10^5$  cells/well. For drug treatment experiments, we treated fibroblast with erastin 5 µM and/or rapamycin  $(5 \mu M)$ , 3-methylaldehyde (2 m M). After treat for 11 h, the cells were harvested, washed with phosphate-buffered saline (PBS), and stained using the propidium iodide (PI) cell death Detection Kit (Becton Dickinson, San Jose, CA, USA). Measurements were performed on a FACSCalibur (Becton Dickinson, San Jose, CA, USA) flow cytometer. Fluorescence of each probe was measured using FlowJo software program. The mean percentages  $\pm$  SD of positive cells per total cells are shown in plots.

#### siRNA and transient transfection

Mouse LC3B, BECN1, and control scramble-siRNA were from Bioneer Corporation (Deajeon, South Korea). Fibroblastic cells were transfected with siRNA at 0.1  $\mu$ M using FuGENE6 transfection reagent (Roche, Indianapolis, IN, USA)) according to the manufacturer's instructions. The sequences of siRNA were as follows: mouse lc3b (sence sequence: GUG GUU GUC AAG UGG UAG A (dTdT), antisence sequence: UCU ACC ACU UGA CAA CCA C (dTdT)); mouse - becn1 (sence sequence: GAC CAU GCA AUG GUA GC U (dTdT), antisence sequence: AAG CUA CCA UUG CAU GGU C (dTdT)).

#### Immunoblot analysis

All samples were lysed with radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 1 mM phenylmethylsulfonylfluoride (PMSF), 1 mM sodium orthovanadate, 1× sigma protease inhibitor cocktail) in ice for 30 min. Lysates were then guantified via Pierce<sup>®</sup> BCA Protein Assay Kit (Thermo scientific, Rockford, IL, USA). In total, 10-50 µg of protein was separated by 10-15% SDS-PAGE and then transferred onto Immobilon<sup>®</sup>-P membrane (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk/ TBS-T for 1 h and incubated with primary antibodies for overnight at 4°C. After washed three times, the membranes were incubated with HRP-conjugated secondary antibodies for 40 min at room temperature. After 1.5 h washing, protein bands were visualized using Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA).

#### Iron assay

Levels of total iron were analyzed in wild type, BECN1<sup>+/-</sup>, and LC3B<sup>-/-</sup> fibroblastic cells using the kit as described<sup>26</sup>. An iron assay kit (Abcam, Cambridge, MA) was subsequently used to quantify total iron in the cell lysates according to manufacturer's instructions. Briefly, cells were harvested from a confluent T75 for each analysis. Cells can be lysed in 4 volume of iron assay buffer, centrifuge at 16,000 × g for 10 min to remove insoluble materials. Five microliters of iron reducer were added into 50 µl samples for total iron (Fe<sup>3+</sup> plus Fe<sup>2+</sup>) assay. Next, 100 µL iron probe solution was added into samples and incubated at 25 °C for 60 min protected from light. Spectrophotometry was used to detect absorbance at 593 nm wavelength.

#### Assessment of cytosolic ROS and lipid peroxidation

Cells were seeded at  $3 \times 10^5$  cells per well in 6-well plates. Next day, cells were treated with erastin  $(10 \,\mu\text{M})$ and/or chloroquine (5  $\mu$ M), 3-methylaldehyde (10  $\mu$ M) for 8 h. After 8 h, cells were incubated with 2 mM CellROX® Deep Red (cytosolic ROS) or 2 µM C11-BODIPY581/591 (lipid peroxidation) (Invitrogen, Life Technologies, Grand Island, NY) for 30 min at 37 °C in the dark. After 30 min of loading, unincorporated dye was removed by washings with 2% FBS containing PBS. Samples were then centrifuged at 1000 rpm for 3 min and the pellets were resuspended in 500 µL of 2% FBS containing PBS Measurements were performed on a FACSCalibur (Becton Dickinson, San Jose, CA, USA) flow cytometer. Fluorescence of each probe was measured using FlowJo software program. The mean percentages ± SD of positive cells per total cells are shown in plots.

#### Statistical analysis

All results were confirmed in at least three independent experiments; data from one representative experiment are shown. Quantitative data are shown as means  $\pm$  standard deviation and significance of statistical analysis was determined with two-tailed, unpaired Student's *t*-test. *P*-values < 0.05 were considered significant.

#### Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A6A1030318).

#### Conflict of interest

The authors declare that they have no conflict of interest.

#### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-019-2064-5).

Received: 8 October 2018 Revised: 18 September 2019 Accepted: 2 October 2019 Publiched online: 28 October 2010

Published online: 28 October 2019

#### References

- Pantopoulos, K., Porwal, S. K., Tartakoff, A. & Devireddy, L. Mechanisms of mammalian iron homeostasis. *Biochemistry* 51, 5705–5724 (2012).
- Muckenthaler, M. U., Galy, B. & Hentze, M. W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. *Annu. Rev. Nutr.* 28, 197–213 (2008).
- Dixon, S. J. & Stockwell, B. R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9–17 (2014).
- Klionsky, D. J. Autophagy revisited: a conversation with Christian de Duve. *Autophagy* 4, 740–743 (2008).
- Yorimitsu, T. & Klionsky, D. J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 12, 1542–1552 (2005).
- Kabeya, Y. et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J.* 19, 5720–5728 (2000).
- Yu, L. et al. Autophagic programmed cell death by selective catalase degradation. Proc. Natl Acad. Sci. USA 103, 4952–4957 (2006).
- Liu, Y. et al. Autosis is a Na<sup>+</sup>,K<sup>+</sup>-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. *Proc. Natl Acad. Sci. USA* **110**, 20364–20371 (2013).
- 9. Carlomagno, F. Ferritinophagy and cell cycle control. Blood 128, SCI-20 (2016).
- Xie, Y. et al. Ferroptosis: process and function. *Cell Death Differ.* 23, 369–379 (2016)
- 11. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* **149**. 1060–1072 (2012).
- Ma, S. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. *PLoS ONE* 12, e0182921 (2017).
- Gao, M. et al. Ferroptosis is an autophagic cell death process. *Cell Res.* 26, 1021–1032 (2016).
- Hou, W. et al. Autophagy promotes ferroptosis by degradation of ferritin. *Autophagy* 12, 1425–1428 (2016).
- Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 12, 1–222 (2016).
- Kwon, M. Y., Park, E., Lee, S. J. & Chung, S. W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. *Oncotarget* 6, 24393–24403 (2015).
- Ganz, T. & Nemeth, E. Hepcidin and iron homeostasis. *Biochim Biophys. Acta* 1823, 1434–1443 (2012).

- Mancias, J. D., Wang, X., Gygi, S. P., Harper, J. W. & Kimmelman, A. C. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature* 509, 105–109 (2014).
- Mancias, J. D. et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. *Elife* 4, e10308 (2015).
- Qian, Z. M., Li, H., Sun, H. & Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. *Pharmacol. Rev.* 54, 561–587 (2002).
- Yang, W. S. & Stockwell, B. R. Ferroptosis: death by lipid peroxidation. *Trends Cell Biol.* 26, 165–176 (2016).
- Levine, B. & Klionsky, D. J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. *Dev. Cell.* 6, 463–477 (2004).
- Colombo, M. I. Autophagy: a pathogen driven process. *IUBMB Life.* 59, 238–242 (2007).
- 24. Qu, X. et al. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. *Cell* **128**, 931–946 (2007).
- Kang, R. & Tang, D. Autophagy and ferroptosis—What's the connection? *Curr.* Pathobiol. Rep. 5, 153–159 (2017).
- Reed, J. C. & Pellecchia, M. Ironing out cell death mechanisms. *Cell* **149**, 963–965 (2012).